C5 and central nervous system disorder: Generating single‐chain variable or other small recombinant fragments from the CDRs of BB5.1 may allow proof‐of‐concept studies for C5 blockade in diseases of the central nervous system where the blood–brain barrier is grossly intact, blocking ingress of intact mAbs.